MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 12.5mg/50mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet Plus 25mg/100mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

No special precautions for storage.

Provenance

Compatibility information derived from Zavesca 100mg capsules (Janssen-Cilag Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Vipdomet 12.5mg/1000mg tablets (Takeda UK Ltd).

Stability Notes

Protect from moisture. Protect from light.

Provenance

This compatibility recommendation is derived from Eucreas 50mg/850mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

Protect from moisture. Protect from light.

Provenance

This compatibility recommendation is derived from Eucreas 50mg/1000mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Politid XL 75mg capsules (Accord Healthcare Ltd).

Stability Notes

Unsuitable for MCA. Keep in the original package to protect from light and moisture.

Stability Notes

Protect from moisture and light.

Provenance

This compatibility recommendation is derived from Famvir 250mg tablets (Phoenix Labs Ltd).

Stability Notes

Store in an airtight container and protect from light.

Provenance

This compatibility recommendation is derived from Circadin 2mg modified-release tablets (Flynn Pharma Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.